Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1441-1460 of 1,738 trials

T-Guard for Early Diffuse Cutaneous Systemic Sclerosis

We are studying the safety and effectiveness of T-Guard in patients with early diffuse cutaneous systemic sclerosis. This trial will help us understand how well the treatment works and how it is processed in the body.

Diffuse Systemic Sclerosis1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyInternal MedicineRheumatology

Lung Cancer Treatment: Immunotherapy and Radiation

We are studying a new treatment combining immunotherapy and radiation for elderly or unfit patients with advanced lung cancer. The aim is to see if this approach improves survival and quality of life.

Unresectable Stage III Non-Small Cell Lung Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Myeloma Treatment: Elranatamab vs. Daratumumab

We are studying whether elranatamab combined with lenalidomide helps patients with newly diagnosed myeloma maintain remission better than daratumumab with lenalidomide after a transplant. This trial will also assess safety and quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Bladder Cancer: V940 and BCG Combination Study

We are investigating whether a new treatment, V940, combined with BCG can improve outcomes for people with high-risk non-muscle invasive bladder cancer compared to BCG alone. This study will also assess the safety of all treatment options.

Bladder Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Rheumatoid Arthritis: CIT-013 Study

We are investigating a new medication, CIT-013, for people with moderately active rheumatoid arthritis. The study aims to see if it helps reduce disease activity and to understand its safety.

Moderately Active Rheumatoid Arthritis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Pancreatic Cancer: Hyperpolarized Pyruvate Imaging Study

We are testing a new imaging technique using hyperpolarized pyruvate in patients with pancreatic cancer. This study aims to confirm its safety and gather data to help improve future treatments.

Pancreatic Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Ovarian Cancer: Olaparib and Bevacizumab Study

We are studying how well a new test identifies genetic markers in patients with advanced ovarian cancer and whether combining Olaparib with Bevacizumab improves treatment outcomes. This trial aims to evaluate the safety and effectiveness of this drug combination.

Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Multiple Myeloma: New Treatment Combinations

We are studying a combination of new medications for people with newly diagnosed multiple myeloma who can undergo a transplant. The goal is to evaluate their safety and effectiveness in improving treatment outcomes.

Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Scarred Vocal Folds: Autologous Fat Injection Study

We are investigating whether an injection of fat-derived cells can improve voice quality in individuals with scarred vocal folds. This study compares the treatment to a placebo to assess its effectiveness and safety.

Scarred Vocal Folds>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

CD20-Positive Acute Lymphoblastic Leukemia: Obinutuzumab vs. Rituximab

We are comparing two treatments, obinutuzumab and rituximab, for adults with newly diagnosed CD20-positive acute lymphoblastic leukemia. The goal is to see which treatment helps more patients achieve complete remission safely.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Total Hip Replacement: Tranexamic Acid Injection

We are studying whether injecting Tranexamic acid into the hip joint can reduce blood loss during total hip replacement surgery. This trial compares the effects of TXA with a placebo to see which is more effective.

Hip Osteoarthritis>2 yearsEfficacy phase (II)Standard MedicinesHematologyOrthopedics and Traumatology

Dental Implants: Antibiotic Use in Bone Augmentation

We are studying whether short or long-term antibiotic use is more effective during dental implant surgery. This trial will also look at how these antibiotics affect bacteria in the mouth and gut.

Need for Oral Bone Augmentation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Improving Ovarian Reserve: rhLH Treatment Study

We are investigating whether a hormone treatment can increase the number of healthy follicles in women trying to conceive. This study aims to assess its effects on fertility and overall safety.

Assisted Fertilization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Breast Cancer: Palbociclib and Fulvestrant Study

We are investigating if a new treatment combination can help prevent relapse in patients with ER positive HER2 negative breast cancer. This study focuses on those with detectable tumor DNA during treatment.

ER Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HER2 Mutated Solid Tumors: Sevabertinib Study

We are studying how well sevabertinib tablets work and their safety for patients with solid tumors that have HER2 mutations. This research may help improve treatment options for these patients.

Pancreatic CancerUrothelial CarcinomaGallbladder Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineOncology

Chronic Pain After Mastectomy: Comparing Treatments

We are studying the effectiveness of Serratus Plane Block, capsaicin, and botulinum toxin type A for managing chronic neuropathic pain after mastectomy. This trial aims to find out which treatment offers better pain relief for those not helped by standard therapies.

Post-Mastectomy Pain Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOncology

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Congenital Nephrogenic Diabetes Insipidus: Fluconazole Study

We are testing whether fluconazole can help people with congenital nephrogenic diabetes insipidus reduce excessive urination and improve their quality of life. This study focuses on patients with a specific AVPR2 gene mutation.

Congenital Nephrogenic Diabetes Insipidus≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrology